Mechanism of Action
References: 1. Aimovig® Core Data Sheet v2.3. 2. Shi L, et al. J Pharmacol Exp Ther 2016; 356: 223-231. 3. Foltz IN, et al. Circulation 2013; 127(22): 2222-30. 4. Levin M, et al. Headache 2018; 58 (10): 1689-1696...
References: 1. Aimovig® Core Data Sheet v2.3. 2. Shi L, et al. J Pharmacol Exp Ther 2016; 356: 223-231. 3. Foltz IN, et al. Circulation 2013; 127(22): 2222-30. 4. Levin M, et al. Headache 2018; 58 (10): 1689-1696...
A meta-analysis was performed based on scientific articles on databases of Genentech and Novartis and a systematic research of articles on PubMed, Medline, Web of Science & Embase with inclusion criteria:
Patients with CSU treated with...Figure 3: Dosing Xolair(r) – omalizumab1. Adapted from SmPC Xolair(r) (EMA, 2020)
The indicated dose for patients with chronic spontaneous urticaria is 300 mg (2 x 150 mg). It is administered by subcutaneous injection every 4...
Omalizumab is a humanized monoclonal antibody. The active substance will selectively bind to IgE causing a reduction in the binding of IgE to the FceRI receptor found on mast cells, among others. It is not entirely clear how this leads to an...
Xolair is indicated as add-on therapy 1 :
For the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and older) patients who do not respond adequately to H1 antihistamine...